|
|
|
Volumn 120, Issue 2, 2016, Pages 228-232
|
|
NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY
a a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALIROCUMAB;
BOCOCIZUMAB;
EVOLOCUMAB;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
MONOCLONAL ANTIBODY;
PCSK9 PROTEIN, HUMAN;
PROPROTEIN CONVERTASE 9;
SERINE PROTEINASE;
CORONARY ARTERY DISEASE;
DRUG EFFECTS;
HUMAN;
HYPERLIPIDEMIAS;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
RISK FACTOR;
RNA INTERFERENCE;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CHOLESTEROL, LDL;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
CORONARY ARTERY DISEASE;
HUMANS;
HYPERLIPIDEMIAS;
PROPROTEIN CONVERTASE 9;
PROPROTEIN CONVERTASES;
RISK FACTORS;
RNA INTERFERENCE;
SERINE ENDOPEPTIDASES;
|
|
EID: 85015675094
PISSN: 00487848
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (9)
|
|
References (0)
|